# Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

> **NCT05833984** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 309 (estimated)

## Conditions studied

- Solid Tumor
- Classic Hodgkin Lymphoma

## Interventions

- **DRUG:** IMM01
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05833984
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-17
- **Primary completion:** 2024-02-07
- **Final completion:** 2024-11-20
- **Target enrollment:** 309 (ESTIMATED)
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05833984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05833984, "Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05833984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*